Member Info for mulledwine

Interim Management Statement Informa plc ("Informa" or the "Group") is releasing an interim management statement providing an update on the performance and financial position of the Group since the half year ended 30 June 2012 based on the results for the nine months ended 30 September 2012 with comments reflecting trading up until the date of this release. Highlights Full year expectations remain unchanged Quality of group earnings continues to improve through pro-active portfolio optimisation Highly attractive cash dynamics - on track for 100% full year cash conversion Group nine month organic revenue growth of -2% Academic Information trading in line, resilient business model Profit growth on track at PCI, despite ongoing market weakness and product rationalisation Large events growing strongly, smaller conferences and corporate training still muted

http://www.investegate.co.uk/Article.aspx?id=20121016071600T8638

"We are excited to be offering Pay in Your Currency to our merchants and their international customers in Taiwan," said Amy Hsia, Head of Payment Service Division, at Taishin Bank. "Providing innovative and superior solutions to our merchants is a top priority, and we are thrilled to be partnering with Planet Payment to continue to do so." "Planet Payment is eager to work with Taishin Bank to expand our presence in Taiwan, making Pay in Your Currency more readily available to merchants, as well as to international travelers visiting the region," said Raymond Tang, General Manger for Greater China at Planet Payment. "We believe it is a positive, value-added service for Taishin Bank, their merchants and their customers."

Taishin Bank and Planet Payment Launch Pay in Your Currency in Taiwan Taishin International Bank Co., Ltd and Planet Payment, Inc. (UK: LSE: AIM: PPT and PPTR; USA: OTCQX: PLPM), a leading multi-currency payment and data processor, today announced they are now offering Planet Payment's Pay in Your Currency® service to Taishin Bank's portfolio of merchants in Taiwan. Pay in Your Currency can offer significant value-added benefits to Taishin merchants and their customers in Taiwan. Pay in Your Currency allows eligible international customers to be offered the choice of paying in their home currency at the point-of-sale. The customers are presented with a receipt or terminal that displays the transaction amounts in New Taiwan Dollars and their home currency, together with the exchange rate and other service details. The customer then selects their currency choice on the receipt or device. With Pay in Your Currency, international travelers can enjoy a more comfortable shopping experience by knowing the amount they are paying in their home currency. Simultaneously, the merchant is provided with an opportunity to reduce the processing costs incurred on these transactions. Merchants continue to receive all funding directly from Taishin Bank in New Taiwan Dollars, with the same funding schedule as their domestic transaction activity, avoiding any potential complications or funding delays. They are able to take advantage of the Taishin and Planet Payment solution through their standard Taishin merchant account.

http://www.investegate.co.uk/Article.aspx?id=201210150700126516O

Some very decent amounts in the results...with little or no reaction in SP

COMMENT Commenting on the drill results, Marcus Engelbrecht, Managing Director and CEO, said: "Toka Tindung continues to demonstrate its potential as a multi-million ounce mine deposit, with more excellent results from our near site exploration programme. These results are extremely exciting and again demonstrate the prospective nature of Toka Tindung. Following our 2011 exploration programme, we were able to increase the mine life by more than 50%. Combined with the results reported earlier in the year, these high-grade intercepts now have the potential to again materially increase our economically defined gold resource, providing a further platform for growing our production profile and increasing shareholder value."

http://www.investegate.co.uk/Article.aspx?id=201210150700096707O

Valuation: DCF valuation of £130m Our valuation of Proteome Sciences has increased by £3m to £130m (67p/share), because of minor amendments to our model following the H112 results. It still includes a 75% risk adjustment on PS biomarker service revenues. The next catalysts could be PS biomarker service contracts, the AD biomarker data or licensing deals.

http://www.edisoninvestmentresearch.co.uk/researchreports/Proteomeupdate151012.pdf

Outlook Taking account of the adverse exchange variance of £0.2 million referred to earlier, trading in the first half is in line with management expectations. We are pleased with initial progress with Omega Dx and continue to see India as offering excellent growth opportunities. However, there remains uncertainty over certain external factors, particularly in Germany with the evolving reimbursement landscape, potential for further weakness in the Euro and product registration delays, which makes progression towards meeting expectation in the second half predicated on generating a contribution from CD4. Whilst the delay with the iSYS allergy development programme clearly has an impact on the timing of future revenues, this disappointment masks the fact that technical risk with the project is at its lowest point since the programme started. Furthermore, the excitement generated with our pre-launch of the CD4 test at the AIDS Conference in Washington DC cements our belief that the opportunity for CD4 in the next financial year and beyond is substantial and overall, our revenue and financial outlook remains unchanged over the coming years.

Infectious Disease CD4 We pre-launched the CD4 test for monitoring T-cells in HIV positive patients at the 19th International AIDS Conference in Washington DC in July of this year. The test generated a significant amount of interest at the conference from global aid organisations and major IVD companies, active in the HIV/AIDS arena. Feedback received subsequently supports the view that the opportunity for this product could be transformational to the Group's prospects in the near-term. The Group is accelerating its scale up plans to meet an earlier anticipated demand and is in discussions with lending institutions in this regard. The process to transfer the technology from the Burnet Institute has continued apace and we aim to be in a position to provide commercial quantities of product for evaluation, coinciding with World AIDS Day on 1 December 2012. BRIC Strategy India Omega Dx (Asia) commenced direct selling of product in India in July of this year. We now have a very experienced team on the ground and the transition of business from the previous distributor has happened with no disruption in the supply of products to customers. In the two full months of August and September, Omega Dx has already achieved a run rate in sales comparable to the previous distributor's performance which is a significant achievement in reversing what had been a declining trend. We have also signed an agreement with SRL Diagnostics covering the distribution of Food Detective® in India which is the subject of a separate announcement today. China The process of registering Food Detective® in China is taking longer than anticipated. This will affect prospective sales for the remainder of the year as compared to management's original expectation, with no certainty of when the registration process will be complete at this stage.

IDS-iSYS With regard to the allergy programme to develop a test panel to be run on the automated IDS-iSYS system, the first seven allergens have now completed the optimisation phase and are undergoing the final claim-support phase. This final phase of the programme seeks to build robustness into the combined reagent-instrument system so that manufacturing consistency can be attained. Recent experiments have provided data suggesting we will need more time to achieve this aim and it is prudent and correct that we maintain high standards of development protocol in reaching our goals. Subsequent groups of allergens have made progress with regard to feasibility and optimisation activities in significantly shorter timescales than it took for the first batch of seven allergens. However, a lack of availability of patient serum samples has resulted in longer lead times in providing enough material for optimisation. Alternative supply sources are being investigated and tested to help alleviate this issue. We estimate that the combined effect of the two matters referred to above could add up to nine months to the planned launch date for a panel of 40-50 tests, taking us to 31 December 2013.

Allergy and Autoimmune Germany The situation around reimbursement in Germany is still expected to take some time to clarify but there have been some changes to report. Out of 17 federal regions, seven have come to a decision on whether to accept national recommendations of a reduced reimbursement rate for lab tests conducted on a doctor's premises. Five of these seven have maintained their current reimbursement position leaving the mechanism largely unchanged. However, two regions have adopted the new guidelines of reduced reimbursement rates, including Hamburg where a larger proportion of the Group's sales are. These changes are currently being appealed by doctors in those two areas. The particularly wet Spring and Summer weather has also had an effect on weakening the pollen season in comparison with the prior period. These external factors have affected sales with a 4% decline in euro terms. The weakening of the euro against sterling has also had an impact such that reported sales in sterling are lower by 13%. Export The on-going process to increase export sales has resulted in completion of an amended software format. There remains a requirement to combine this with an improved product format and the intention is to launch this improved product offering at the World Allergy Congress in Hyderabad, India in December 2012.

Trading Update & Notice of Results Omega, the AIM listed medical diagnostics company, announces the following trading update for the six months to 30 September 2012, in advance of releasing its interim results on Wednesday 21 November 2012. Turnover is expected to be in line with the same period last year at £5.53 million; inclusive of an adverse exchange rate impact in Germany of £0.2 million. The expected breakdown of turnover by segment is as follows: · Food intolerance revenue up by 15% to £2.12 million (2011: £1.84 million) · Allergy and autoimmune revenue down by 11% to £2.03 million (2011: £2.28 million) · Infectious disease/other revenue down by 2% to £1.38 million (2011: £1.41 million) Food Intolerance Sales of Food Intolerance products and services continue to show resilience in the face of difficult economic headwinds with the rise in sales ahead of our expectations in the first half. Average revenue per Genarrayt® instrument (excluding Spain) is expected to continue its rising trend and Food Detective® continues to benefit from its unique market position.

http://www.investegate.co.uk/Article.aspx?id=201210150700076504O

Investec has downgraded its rating for information management group SDL from 'buy' to 'hold' after Monday's trading update showed that the slowdown in technology revenue growth continued into the third quarter.

Jefferies has upgraded its rating for sweeteners and food products group Tate & Lyle from 'hold' to 'buy' and raised its target price from 690p to 800p, saying that the stock currently offers a 'compelling buying opportunity'. "We argue that the company has laid a strong foundation for a sustainable growth profile and see the current valuation as a compelling buying opportunity to enjoy future re-rating towards specialty peers on c15x."

Update on exploration In the third quarter of 2012 intensive exploration continued at 10 projects and nine prospects with 60 rigs, completing 212,200 metres of core and 60,000 metres of reverse circulation drilling. Resources were increased at each of our seven operating mines, and reserves notably increased at Noche Buena and Saucito. Updated resource and reserve figures will be audited at year end and published in early March of 2013. Near surface gold bearing structures are in exploration at Noche Buena East and Tajitos in the Herradura District. Higher gold values than were expected were also obtained in drilling at the Centauro Deep project below the main Herradura pit. Exploration continues south of the Fresnillo mine testing the extensions of known veins and new geophysical targets. At the Ciénega District, infill drilling has intersected economic silver-gold-lead-zinc values on the San Ramón, Cebollitas, and Las Casas veins. Exploration and development ramps and drifts at the San Julián project now total 24 kilometres and parallel gold-silver veins were found in the Todos Santos Norte and Santa Sofía areas. Silver grades in the JM disseminated ore body were confirmed in five development crosscuts. Interesting preliminary results were obtained at the Coneto silver-gold project, a joint venture with Orex in Durango, and the Pilarica project, 100% owned by Fresnillo in Peru. Exploration resumed at the Guanajuato and San Nicolas del Oro silver-gold properties having secured the necessary social and environmental permits. The exploration adit at the Orisyvo gold project was extended to 1100 metres length through the gold-bearing sulphide zone cutting sections grading over 2 g/t, and metallurgical testing of bulk samples is in progress. Infill drilling at the Minera Juanicipio joint venture with MAG Silver continues following the recommendations of the AMC prefeasibility study and the Juanicipio Technical Committe to convert inferred resources to the indicated category.

Octavio Alvídrez, Chief Executive Officer, said: "The Group's performance over the period demonstrates our commitment to maximise sustainable growth through the continued ramp up of Saucito and the new Noche Buena mine. These have allowed us to reach record levels of attributable gold production and maintain silver production levels in the year to date. We are on track to achieve our silver and gold production targets for 2012. Higher ore throughput from Ciénega and an increase in ore deposited at Herradura also benefited gold production. Our growing position as a significant gold producer will be further consolidated by continued progress at our development projects. Although year to date attributable silver production decreased, due to the anticipated and previously announced decline in Fresnillo's ore grades, this was in part offset by higher silver ore grades processed at Ciénega and Saucito. Our exploration projects are the cornerstone of our future growth. As a result we are pleased to announce that significant progress has been made in the drilling programme in the Herradura District where encouraging results were obtained at Tajitos. Further progress was also made in San Julián where encouraging drilling results are being evaluated. As part of our sustainable growth perspective, Fresnillo is committed to the wellbeing of our workers and contractors. As a result we are deeply saddened and concerned by the fatalities experienced this quarter. We have therefore further refined our safety programmes as we continue in our pursuit of achieving zero accidents. Looking to the remainder of the year, Fresnillo is confident that it will continue to deliver growth through existing operations and new deposits and remains on track to meet its short and long term aspirations."